ROCHE AND ATEA PARTNERSHIP

Roche walks away from Atea partnership to develop COVID-19 pill

The rights and licenses to AT-527 will return to Atea after the partnership ends in February, and the company said it would continue to develop the treatment and expects data from a late-stage trial in the second half of 2022.